Xilio Therapeutics (NASDAQ:XLO) Given “Buy” Rating at Chardan Capital

Posted by on Jul 14th, 2023

Chardan Capital reiterated their buy rating on shares of Xilio Therapeutics (NASDAQ:XLO – Free Report) in a research report released on Monday, PriceTargets.com reports. Chardan Capital also issued estimates for Xilio Therapeutics’ FY2023 earnings at ($3.22) EPS and FY2024 earnings at ($1.87) EPS.

Xilio Therapeutics Stock Down 2.2 %

NASDAQ:XLO opened at $2.66 on Monday. The firm has a market cap of $73.07 million, a P/E ratio of -0.81 and a beta of 0.19. The company has a debt-to-equity ratio of 0.02, a quick ratio of 5.99 and a current ratio of 5.99. Xilio Therapeutics has a fifty-two week low of $1.95 and a fifty-two week high of $4.92. The firm has a 50-day simple moving average of $2.91 and a two-hundred day simple moving average of $3.04.

Xilio Therapeutics (NASDAQ:XLO – Get Free Report) last released its quarterly earnings data on Tuesday, May 9th. The company reported ($0.83) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.91) by $0.08. Analysts predict that Xilio Therapeutics will post -2.8 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Xilio Therapeutics

A number of institutional investors and hedge funds have recently made changes to their positions in XLO. Dimensional Fund Advisors LP purchased a new position in shares of Xilio Therapeutics in the first quarter worth approximately $57,000. Morgan Stanley lifted its holdings in Xilio Therapeutics by 274.4% during the fourth quarter. Morgan Stanley now owns 25,611 shares of the company’s stock valued at $69,000 after purchasing an additional 18,771 shares in the last quarter. Renaissance Technologies LLC lifted its holdings in Xilio Therapeutics by 30.2% during the fourth quarter. Renaissance Technologies LLC now owns 37,100 shares of the company’s stock valued at $100,000 after purchasing an additional 8,600 shares in the last quarter. Millennium Management LLC purchased a new position in Xilio Therapeutics during the second quarter valued at approximately $146,000. Finally, Bank of New York Mellon Corp lifted its holdings in Xilio Therapeutics by 47.7% during the first quarter. Bank of New York Mellon Corp now owns 21,029 shares of the company’s stock valued at $149,000 after purchasing an additional 6,791 shares in the last quarter. Hedge funds and other institutional investors own 63.91% of the company’s stock.

Xilio Therapeutics Company Profile

(Get Free Report)

Xilio Therapeutics, Inc, a clinical-stage biotechnology company, discovers and develops tumor-activated immuno-oncology therapies. Its checkpoint inhibitor program includes XTX101, an investigational Fc-enhanced, tumor-activated anti-CTLA-4 mAb that is in Phase 1 clinical trial for patients with advanced solid tumors.

Read More

Receive News & Ratings for Xilio Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Xilio Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.